Skip to main content

[vc_row][vc_column][vc_single_image image="48252" img_size="full" alignment="center"][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=""]A new cancer drug, larotrectinib, has in a very early clinical trial been shown to have a 93% (14/15) effectiveness rate for pediatric cancers; that is to say, for not just one cancer, but many. Hailed by the U.S. Food and Drug...

It’s called “the cloud,” but it is not the fluffy white thingees drifting overhead. It promises to revolutionize cancer care. By, of all things, sharing data. “In cancer, only about 4% of patients go on a clinical trial, but that data is not ever really leveraged....